<ul data-eligibleForWebStory="false"><li>Metropolis Healthcare Ltd. reported a 23% year-on-year uptick in revenue growth for the quarter ended June 30, driven by increased patient and test volumes.</li><li>Specialty revenues surged up to 35% year-on-year due to the consolidation of Core Diagnostics, primarily focusing on high-end specialized oncology testing.</li><li>Excluding the acquisition of Core, DAPIC, and Scientific, revenues grew approximately 13% year-on-year, with business-to-consumer revenues up by 15% year-on-year.</li><li>The company mentioned that it is debt-free, and shares of Metropolis Healthcare closed 2.04% higher at Rs 1,773.30 apiece on the NSE.</li></ul>

Metropolis Healthcare Q1 Update: Revenue Up 23%

Discover more